MedTrace Logo

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

NCT02280434 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2016-11-03

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.

Conditions

Interventions

DRUG

CBP-307

DRUG

Placebo

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • Nucleus Network Ltd

    collaborator OTHER

  • Connect Biopharm LLC

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, MD, PhD, FRACP · Nucleus Network

  • Zheng Wei, PhD · Suzhou Connect Biopharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02280434 on ClinicalTrials.gov